Mesoblast Added to S&P/ASX 200 INDEX

Core Viewpoint - Mesoblast Limited has been added to the S&P/ASX 200 Index, effective March 6, 2025, highlighting its significance in the Australian market as a leader in allogeneic cellular medicines for inflammatory diseases [1][2]. Company Overview - Mesoblast is a global leader in developing allogeneic cellular medicines aimed at treating severe and life-threatening inflammatory conditions, utilizing its proprietary mesenchymal lineage cell therapy technology [3][5]. - The company has a strong intellectual property portfolio with over 1,000 granted patents or patent applications, providing commercial protection expected to last until at least 2041 in major markets [6]. Product Development - Mesoblast's RYONCIL® (remestemcel-L) is the first FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older [4]. - The company is developing additional therapies for various inflammatory diseases, including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, as well as rexlemestrocel-L for heart failure and chronic low back pain [5]. Manufacturing Capabilities - Mesoblast employs proprietary manufacturing processes that yield industrial-scale, cryopreserved, off-the-shelf cellular medicines, ensuring availability to patients worldwide [7]. Market Presence - Mesoblast operates in Australia, the United States, and Singapore, and is listed on both the Australian Securities Exchange (ASX: MSB) and Nasdaq (NASDAQ: MESO) [8].